Biotech news, week of June 29, 2026

Machine summary The companies said the trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival. Genmab and AbbVie said they will engage global regulatory authorities and submit the data for presentation at a future medical meeting.

1. Genmab and AbbVie said they will engage global regulatory authorities.

Reported by Pr Newswire and finanznachrichten.de.

• AbbVie
• epcoritamab
• Genmab
• lenalidomide

Machine summary Medicare will begin covering weight-loss drugs on July 1 under a temporary pilot program called Medicare GLP-1 Bridge, according to reports.

1. Medicare will start covering weight-loss drugs on July 1 for the first time under a temporary pilot program, according to reports.
2. The pilot program is called Medicare GLP-1 Bridge.

Reported by wpsdlocal6.com and wxow.com.

• Medicare

Reports ran between 13:45 and 22:45 UTC on Jun 29.

The outlets that reported this event are listed with links to their reports; no summary of ours passed our automated checks for it, which says nothing about the event (how they work).

Reported by ABC News and thegrio.com.

• ALS (Amyotrophic Lateral Sclerosis)

Reported by Wsls, jamaica-gleaner.com, Ksat and theargus.co.uk.

• Venezuela

Machine summary Xellar raised $50 million in Series A financing to build 3D bio intelligence, according to the report title.

1. Founder and CEO Xin Xie says the closed-loop system creates a “flywheel” to generate high-quality human data at scale for drug discovery.
2. The company aims to build biological foundation models and virtual cell systems that can predict drug efficacy and toxicity.
3. Xellar raised $50 million in Series A financing.

Reported by Pr Newswire.

• 3D Bio Intelligence

Machine summary Digiday reported that healthcare and pharma digital ad spending is forecast to reach $26.2 billion, compared with $6.9 billion in traditional spending, with social media surpassing linear TV for the first time in 2025. Sources told Digiday that pharma marketers are increasing spending on specialized ad tech, including DeepIntent, Patient Point and Pulsepoint.

1. Per data cited by Digiday, healthcare and pharma digital ad spending is projected at $26.2 billion, while traditional spending is $6.9 billion.
2. Social media surpassed linear TV for the first time in 2025, according to Digiday.
3. Sources informed Digiday that pharma brand marketers are increasing their focus on specialized ad tech.
4. Some insiders said that, per Digiday, the rise of companies such as DeepIntent, Patient Point and Pulsepoint comes at the expense of legacy platforms, including demand- and sell-side platforms.
5. DeepIntent sold a majority stake to Vitruvian Partners for $637 million in late 2025, according to Digiday.

Reported by Digiday.

• DeepIntent
• Pulsepoint

Machine summary The declaration said the two countries would strengthen cooperation in critical technologies, supply chains and emerging industries, and expressed concern over economic coercion and non-market policies and practices.

Reported by tribuneindia.com and Latestly.

• India
• Japan
• Critical minerals
• semiconductors
• Clean Energy

Full coverage: every report, when each was published, and who was named (2 outlets)

Machine summary Key facts from the reports:

1. A doctor told AAP there is no one specific symptom and people often have non-specific symptoms, according to the reports.

Reported by easternriverinachronicle.com.au, The Leader, thecourier.com.au, portstephensexaminer.com.au, examiner.com.au and Perthnow.